Situation
Hemophilia is a very complex disease. Based on the recommended dosage, the patient therapy have to be carefully thought and tested for each individual. Besides the dosage , all the complexity in the management involves also disease severity, adherence , patient age, amongst other parameters.
We had in hands a very innovative product to treat hemophilia. It has an extended half-life , which at the end results in a lower dosage , with a more spaced posology. The challenge was to roll out a health economic model developed and released by global team throughout the Latin America countries, and adapt such model to each country reality. The main objective was to demonstrate that the use of the innovative drug was more cost effective than the regular drug (current treatment available) using all the parameters involved in the patient management – not only the drug, but also care takers ; adherence (and less hospitalization); reduce bleedings and others
Brix solution
We selected 2 countries to use as reference and studied the available data. After that we worked very close to the global team to propose and get changes in the model that reflected better each country reality. We finally got the positive result we were trying to demonstrate. In this effort we have also to incude KOL’s to get the patient data that was not available publicly . The results were so expressive for one of the countries selected the study was sent for publication in a HE conference.